This website uses cookies to store user session information. By using our website you consent to our terms of use. Read more
I agree
Private post address: Kronovägen 7, 182 73 Stocksund, Sweden

Career

Institution(s) and position(s)
01.01.2001–31.12.2020   
Karolinska Institutet, Stockholm Sweden; Associate Professor
01.05.2010–31.01.2012   
University of Tartu, Faculty of Medicine, Department of Pathological Anatomy and Forensic Medicine, Professor of Pathological Anatomy (0,50)
 
 
Education
1989–1995   
MD, PhD, MBA, qualified physian (legitmerad läkare)
 
 
Creative work
The Stockholm-Tartu Atherosclerosis Reverse Network Engineering Team (STARNET) (2007–)
The goal of this long-term project is to create a database of 1000 CAD patients and 100 non-CAD controls that will include, for each subject, biopsy material from.
 
 
Additional career information
CONFERENCES
Invited keynote speaker at the “Advances in Molecular Mechanisms of Atherosclerosis (J7)” organized by the Keystone Conferences organization in Banff, Canada, 2010
Invited speaker to the “Genetics and Genomics of Cardiovascular Disease Workshop” organized by the North American Vascular Biology Organization (NAVBO), 2009
Organizer and keynote speaker, ESF Exploratory Workshop on Computational Disease Modeling, 2008, Barcelona
Selected to the Program Committee of the International Conference on Systems Biology. ICSB2008, Göteborg, August 23–27, 2008. Moderator of workshop on Cardiovascular Systems Biology
XV International Symposium on Drugs Affecting Lipid Metabolism, Venice, Italy, October 24–27, (2004)
Annual Scandinavian Atherosclerosis Conference, 2004, Humlebeak, Denmark (2002, 2003)
International Symposium on Atherosclerosis (Paris, 1998; Kyoto, 2003)
42nd Annual Conference on Cardiovascular Disease Epidemiology and Prevention, American Heart Association (Hawaii, 2002)
British Atherosclerosis Society (Oxford, 2002,)
European Lipoprotein Club (Tutzing, 1998, 2001)
Atheroma Club (Sweden, 1992, 1996, 1998, 2003, 2006)
;
Karolinska Institutet
Department of Medical Biophysics and Biochemistry (MBB)
The Vascular Biology Unit
The Vascular Genomics group
Scheelesväg 2,
171 77 Stockholm;

Karolinska Institutet
Department of Medical Biophysics and Biochemistry (MBB)
The Vascular Biology Unit
The Vascular Genomics group
Scheelesväg 2,
171 77 Stockholm;
Office address
Karolinska Institutet
Depart. of Medical BioPhysics and Biochemistry
Vascular Biology Unit
The Vascular Genomics group
S-171 77 STOCKHOLM
Telephone +46-8-517 70314
Fax +46-8-517 73120
Date of birth: 10 June 1965
Civil state: Married since 1995 to Gisela Maria Björkegren, with two daughters aged 13 and 11.
PROFESSIONAL PREPARATION
• Master of Business Administration, Stockholm Business School, 1989
• Karolinska Institutet Medical School, June 1995
• Fully qualified physician, May 1998
• M.D., Karolinska Institutet, 1998 (Thesis: “Triglyceride-rich lipoproteins: Postprandial metabolism and composition in relation to atherosclerosis“; external faculty examiner: Professor John Betteridge, University College London)
• Postdoctoral Fellowship, Gladstone Institute of Cardiovascular Disease, University of California, San Francisco, CA (head: Professor Stephen G. Young), January 1999 to December 2001
• Associate Professor (Docent), Molecular Medicine, Karolinska Institutet, 2003
• Research Assistant Professor (FoAss), 2004–2007
• Senior Investigator position, Karolinska Institutet 2008–2009
• Senior investigator position, the Swedish Heart-Lung foundation, 2010-2015
• Senior investigator, permanent position, Karolinska Institutet, 2010-
• Professor of Pathology; Tartu University, 201005-
PREVIOUS AND CURRENT APPOINTMENTS
2010.01.01– Group Leader, Cardiovascular Genomics group, Karolinska Institutet, Stockholm, Sweden
2008.06.01– Medical Advisor, DNA-Guide AB
2006.01.01–2009.12.31 Group Leader, Computational Medicine, Atherosclerosis Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
2004.01.01–2005.12.31 Head, Computational Medicine Unit, Center for Genomics & Bioinformatics, Karolinska Institutet, Stockholm, Sweden
2004.01.01–2005.12.31 Group Leader, Molecular Medicine, Center for Genomics & Bioinformatics, Karolinska Institutet, Stockholm, Sweden
2003.03.01– CEO, Clinical Gene Networks AB
2002.01.01–2003.12.31 Group Leader, Atherosclerosis Research Unit, King Gustaf V Research institute, Karolinska Institutet, Stockholm, Sweden
1999.01.01–2001.12.31 Postdoctoral Fellow, Gladstone Institute of Cardiovascular Disease, University of California, San Francisco
1995.11.01–1998.12.31 Clinical Research/Internship (Forskar-AT), Karolinska Hospital
1995.05.01–995.10.31 Assistant Surgeon, Department of Thoracic Surgery, Karolinska Hospital
1995.02.01–1998.04.30 PhD Student, K. Gustaf V Research Institute, Karolinska Hospital
1992.06.01–1995.01.31 Research Associate, K. Gustaf V Research Institute, Karolinska Hospital
1990.01.01–1991.09.31 Research Associate, Department of Tumor Pathology, Karolinska Hospital
1988.09.05–1989.08.21 Trader, Electrolux Treasury AB.
;

Qualifications

 
 
Field of research
FIELD OF RESEARCH: 3. Health; 3.11. Biochemistry, Genetics, Microbiology, Biotechnology, Molecular Biology, Cell Biology, Biophysics and Bioinformatics relating to Health Studies; SPECIALITY: pathology of atherosclerosis, cardiovascular disease, systems approach, functional genomics, gene networks, mouse genetics, gene-mmodification mouse models
 
 

Publications

Category
Year
Publication
 
1.1.
2015
1.1.
2015
1.1.
2014
1.1.
2014
1.1.
2013
1.1.
2012
1.1.
2011
1.1.
2011
1.1.
2011
1.1.
2011
1.2.
2011
1.1.
2010
1.1.
2009
1.1.
2009
1.1.
2009
1.1.
2009
1.1.
2009
1.1.
2009
1.1.
2009
1.1.
2008
1.1.
2008
1.1.
2008
1.1.
2008
1.1.
2008
1.1.
2008
1.1.
2007
1.1.
2007
1.1.
2007
1.1.
2007
1.1.
2007
1.1.
2007
1.1.
2007
1.2.
2007
3.1.
2007
1.1.
2006
1.1.
2006
1.1.
2006
1.1.
2006
1.2.
2006
3.4.
2006
3.4.
2006
1.1.
2005
1.1.
2005
1.1.
2005
1.1.
2005
1.1.
2005
1.1.
2004
1.1.
2002
1.1.
2002
1.1.
2001
1.1.
2000
1.1.
2000
1.1.
1999
1.1.
1999
1.1.
1998
1.1.
1998
12.07.2019
10.06.1965
+46733568181
johan.bjorkegren@ki.se

Teenistuskäik

Töökohad ja ametid
01.01.2001–31.12.2020   
Karolinska Institutet, Stockholm Sweden; Associate Professor
01.05.2010–31.01.2012   
Tartu Ülikool, Arstiteaduskond, Patoloogilise anatoomia ja kohtuarstiteaduse instituut, patoloogilise anatoomia professor (0,50)
 
 
Haridustee
1989–1995   
MD, PhD, MBA, qualified physian (legitmerad läkare)
 
 
Teadusorganisatsiooniline ja -administratiivne tegevus
2005−2020   
Group leader Tartu University, Faculty of Medicine, Group leader, Vascular Bioogy unit, Depart. of Medical Biochemistry and Biophysics, Karolinska Inst.
 
 
Loometöö
The Stockholm-Tartu Atherosclerosis Reverse Network Engineering Team (STARNET) (2007–)
The goal of this long-term project is to create a database of 1000 CAD patients and 100 non-CAD controls that will include, for each subject, biopsy material from.
 
 
Teenistuskäigu lisainfo
CONFERENCES
Invited keynote speaker at the “Advances in Molecular Mechanisms of Atherosclerosis (J7)” organized by the Keystone Conferences organization in Banff, Canada, 2010
Invited speaker to the “Genetics and Genomics of Cardiovascular Disease Workshop” organized by the North American Vascular Biology Organization (NAVBO), 2009
Organizer and keynote speaker, ESF Exploratory Workshop on Computational Disease Modeling, 2008, Barcelona
Selected to the Program Committee of the International Conference on Systems Biology. ICSB2008, Göteborg, August 23–27, 2008. Moderator of workshop on Cardiovascular Systems Biology
XV International Symposium on Drugs Affecting Lipid Metabolism, Venice, Italy, October 24–27, (2004)
Annual Scandinavian Atherosclerosis Conference, 2004, Humlebeak, Denmark (2002, 2003)
International Symposium on Atherosclerosis (Paris, 1998; Kyoto, 2003)
42nd Annual Conference on Cardiovascular Disease Epidemiology and Prevention, American Heart Association (Hawaii, 2002)
British Atherosclerosis Society (Oxford, 2002,)
European Lipoprotein Club (Tutzing, 1998, 2001)
Atheroma Club (Sweden, 1992, 1996, 1998, 2003, 2006)
;

Karolinska Institutet
Department of Medical Biophysics and Biochemistry (MBB)
The Vascular Biology Unit
The Vascular Genomics group
Scheelesväg 2,
171 77 Stockholm;

Karolinska Institutet
Department of Medical Biophysics and Biochemistry (MBB)
The Vascular Biology Unit
The Vascular Genomics group
Scheelesväg 2,
171 77 Stockholm;
Office address
Karolinska Institutet
Depart. of Medical BioPhysics and Biochemistry
Vascular Biology Unit
The Vascular Genomics group
S-171 77 STOCKHOLM
Telephone +46-8-517 70314
Fax +46-8-517 73120
Date of birth: 10 June 1965
Civil state: Married since 1995 to Gisela Maria Björkegren, with two daughters aged 13 and 11.
PROFESSIONAL PREPARATION
• Master of Business Administration, Stockholm Business School, 1989
• Karolinska Institutet Medical School, June 1995
• Fully qualified physician, May 1998
• M.D., Karolinska Institutet, 1998 (Thesis: “Triglyceride-rich lipoproteins: Postprandial metabolism and composition in relation to atherosclerosis“; external faculty examiner: Professor John Betteridge, University College London)
• Postdoctoral Fellowship, Gladstone Institute of Cardiovascular Disease, University of California, San Francisco, CA (head: Professor Stephen G. Young), January 1999 to December 2001
• Associate Professor (Docent), Molecular Medicine, Karolinska Institutet, 2003
• Research Assistant Professor (FoAss), 2004–2007
• Senior Investigator position, Karolinska Institutet 2008–2009
• Senior investigator position, the Swedish Heart-Lung foundation, 2010-2015
• Senior investigator, permanent position, Karolinska Institutet, 2010-
• Professor of Pathology; Tartu University, 201005-
PREVIOUS AND CURRENT APPOINTMENTS-
2010.01.01– Group Leader, Cardiovascular Genomics group, Karolinska Institutet, Stockholm, Sweden
2008.06.01– Medical Advisor, DNA-Guide AB
2006.01.01–2009.12.31 Group Leader, Computational Medicine, Atherosclerosis Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
2004.01.01–2005.12.31 Head, Computational Medicine Unit, Center for Genomics & Bioinformatics, Karolinska Institutet, Stockholm, Sweden
2004.01.01–2005.12.31 Group Leader, Molecular Medicine, Center for Genomics & Bioinformatics, Karolinska Institutet, Stockholm, Sweden
2003.03.01– CEO, Clinical Gene Networks AB
2002.01.01–2003.12.31 Group Leader, Atherosclerosis Research Unit, King Gustaf V Research institute, Karolinska Institutet, Stockholm, Sweden
1999.01.01–2001.12.31 Postdoctoral Fellow, Gladstone Institute of Cardiovascular Disease, University of California, San Francisco
1995.11.01–1998.12.31 Clinical Research/Internship (Forskar-AT), Karolinska Hospital
1995.05.01–995.10.31 Assistant Surgeon, Department of Thoracic Surgery, Karolinska Hospital
1995.02.01–1998.04.30 PhD Student, K. Gustaf V Research Institute, Karolinska Hospital
1992.06.01–1995.01.31 Research Associate, K. Gustaf V Research Institute, Karolinska Hospital
1990.01.01–1991.09.31 Research Associate, Department of Tumor Pathology, Karolinska Hospital
1988.09.05–1989.08.21 Trader, Electrolux Treasury AB.
;

Kvalifikatsioon

 
 
Teaduspreemiad ja tunnustused
2010, Lars Johan Markus Björkegren, Invited speaker to the Rudbeck Seminar series, Uppsala University, 2008 PROSANA lecturer, December 2007 Finalist in the Young Investigator Award, International Symposium on Atherosclerosis, Kyoto, 2003 Swedish Research Council/Fogarty-Fellowship, 199
 
 
Teadustöö põhisuunad
VALDKOND: 3. Terviseuuringud; 3.11. Terviseuuringutega seotud uuringud, näiteks biokeemia, geneetika, mikrobioloogia, biotehnoloogia, molekulaarbioloogia, rakubioloogia, biofüüsika ja bioinformaatika; PÕHISUUND: pathology of atherosclerosis, cardiovascular disease, systems approach, functional genomics, gene networks, mouse genetics, gene-mmodification mouse models
 
 
Lisainfo
NATIONAL RESEARCH COLLABORATIONS
Professor Anders Hamsten, Karolinska Institutet, Karolinska University Hospital, Solna. Nature of collaborations: Genetic validation of gene expression targets.
Mehran Salehpour, PhD, Associate Professor of Ion Physics, Ångström Laboratory, Uppsala University. Nature of collaborations: Carbon 14 measurements to determine actual age of atherosclerosis plaques in humans.
Docent Olle Mellander, Lunds Universitet, Nature of collaborations: Genetics of CAD
Professor Per Eriksson, Karolinska Institutet, Karolinska University Hospital, Solna. Nature of collaborations: Molecular evaluation of atherosclerosis target genes.
Associate Professor Michael Hörnquist, Department of Science and Technology ITN, Linköping Institute of Technology. Nature of collaborations: Integration of public medical datasets in the analysis of gene networks in atherosclerosis.
Professor Peter Arner, Karolinska Institutet, Huddinge. Nature of collaborations: Role of apoB in fat cell lipolysis.
INTERNATIONAL RESEARCH COLLABORATORS
Eric E. Schadt, PhD, CSO, Pasific Biosciences, Palo Alto. Nature of collaborations: Integration of DNA variation data and expression phenotypes and networks in complex diseases.
Arno Ruusalepp, MD, PhD, Tartu University Hospital, Heart Surgeon, Estonia.
Aldons J. Lusis, MD, PhD, Professor, Department of Molecular Medicine, UCLA. Nature of collaborations: Mouse models of atherosclerosis, systems approaches
Nelish Samani, PhD, MD, Professor, Leicester University, UK. Nature of collaborations: Genome-wide associations studies (GWAS) of CAD (WTCCC)
Heribert Schunkert, PhD, MD, Professor, Lubeck, Germany. GWAS of CAD
TOP-10 PUBLICATIONS
1. Hägg S, Skogsberg J, Lundström J, Noori P, Nilsson R, Zhong H, Maleki S, Shang MM, Brinne B, Bradshaw M, Bajic VB, Samnegård A, Silveira A, Kaplan LM, Gigante B, Leander K, de Faire U, Rosfors S, Lockowandt U, Liska J, Konrad P, Takolander R, Franco-Cereceda A, Schadt EE, Ivert T, Hamsten A, Tegnér J, Björkegren J. Multi-organ expression profiling uncovers a gene module in coronary artery disease involving transendothelial migration of leukocytes and LIM domain binding 2: the Stockholm Atherosclerosis Gene Expression (STAGE) study. PLoS Genet. 2009 Dec;5(12):e1000754.
Comment: A key paper for our systems approach to coronary atherosclerosis using a top-down approach – unbiased identification of a gene module important for atherosclerosis severity.
2. Skogsberg J, Dicker A, Rydén M, Aström G, Nilsson R, Bhuiyan H, Vitols S, Mairal A, Langin D, Alberts P, Walum E, Tegnér J, Hamsten A, Arner P, Björkegren J. ApoB100-LDL acts as a metabolic signal from liver to peripheral fat causing inhibition of lipolysis in adipocytes. PLoS ONE 2008;3:e3771.
Comment: Apolipoprotein B100 is the largest protein in the human body and one of the most widely studied. We identified an unexpected and completely novel function of apoB100 as a regulator of adipocyte lipolysis. This discovery was made possible by cross-disciplinary research combining experimental studies in mice and cell cultures with clinical observations in patients.
3. Skogsberg J, Lundström J, Kovacs A, Nilsson R, Noori P, Maleki S, Köhler M, Hamsten A, Tegnér J, Björkegren J. Transcriptional profiling uncovers a network of cholesterol-responsive atherosclerosis target genes. PLoS Genet. 2008;4:e1000036.
Comment: A key paper for our systems approach to atherosclerosis using time-series of global gene expression profiles in our unique mouse model of atherosclerosis.
4. Kovacs A, Tornvall P, Nilsson R, Tegnér J, Hamsten A, Björkegren J. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci USA 2007;104:13768–13773.
Comment: This study contradicts the common belief that C-reactive protein promotes atherosclerosis.
5. Tegnér J, Skogsberg J, Björkegren J. Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Multi-organ whole-genome measurements and reverse engineering to uncover gene networks underlying complex traits. J. Lipid Res. 2007;48:267–277.
Comment: Invited review that summarizes our systems approach to coronary artery disease and atherosclerosis and serves as a supplement to the short research program enclosed in this application.
6. Tegnér J, Björkegren J. Perturbations to uncover gene networks. Trends Genet. 2007;23:34–41.
Comment: Invited review demonstrating the principals of gene network identification.
7. Hamsten A, Silveira A, Boquist S, Tang R, Bond MG, de Faire U, Björkegren J. The apolipoprotein CI content of triglyceride-rich lipoproteins independently predicts early atherosclerosis in healthy middle-aged men. J. Am. Coll. Cardiol. 2005;45:1013–1017.
Comment: This publication indicates for the first time that the apoCI content of triglyceride-rich lipoproteins independently promotes atherosclerosis in otherwise healthy men.
8. Larsson S, Skogsberg J, Björkegren J. The low density lipoprotein receptor prevents secretion of dense apoB100-containing lipoproteins from the liver. J. Biol. Chem. 2004;279:831–836.
Comment: First major paper as senior author.
9. Björkegren J, Veniant M, Kim SK, Withycombe SK, Wood PA, Hellerstein MK, Neese RA, Young SG. Lipoprotein secretion and triglyceride stores in the heart. J. Biol. Chem. 2001;276:38511–38517.
Comment: Main paper from my postdoctoral fellowship in the U.S. (1999–2001).
10. Björkegren J, Boquist S, Samnegard A, Lundman P, Tornvall P, Ericsson CG, Hamsten A. Accumulation of apolipoprotein C-I-rich and cholesterol-rich VLDL remnants during exaggerated postprandial triglyceridemia in normolipidemic patients with coronary artery disease. Circulation 2000;101:227–230.
Comment: Key paper from my studies of apoCI.
SUMMARY OF PUBLISHED PAPERS: 57 (1–5, thesis; 6–49, peer-reviewed publications; 50–57, peer-reviewed reviews, +9 papers submitted/manuscripts (not shown)). Some computational publications are not in PubMed. Conference publications are in the field of mathematics highly considered.
Thesis (1998)
1. Karpe F, Bell M, Björkegren J, Hamsten A. Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler. Thromb. Vasc. Biol. 1995;15:199–207.
2. Björkegren J, Packard CJ, Hamsten A, Bedford D, Caslake M, Foster L, Shepherd J, Stewart P, Karpe F. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J. Lipid Res. 1996;37:76–86.
3. Björkegren J, Hamsten A, Milne RW, Karpe F. Alterations of VLDL composition during alimentary lipemia. J. Lipid Res. 1997;38:301–314.
4. Björkegren J, Karpe F, Milne RW, Hamsten A. Differences in apolipoprotein and lipid composition between human chylomicron remnants and very low density lipoproteins isolated from fasting and postprandial plasma. J. Lipid Res. 1998;39:1412–1420.
5. Björkegren J, Karpe F, Vitols S, Tornvall P, Hamsten A. Transient triglyceridemia in healthy normolipidemic men increases cellular processing of large very low density lipoproteins by fibroblasts in vitro. J. Lipid Res. 1998;39:423–436.
1999–
6. Boquist S, Ruotolo G, Tang R, Björkegren J, Bond MG, de Faire U, Karpe F, Hamsten A. Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation 1999;100:723–728.
7. Raabe M, Veniant MM, Sullivan MA, Zlot CH, Björkegren J, Nielsen LB, Wong JS, Hamilton RL, Young SG. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J. Clin. Invest. 1999;103:1287–1298.
8. Björkegren J, Boquist S, Samnegard A, Lundman P, Tornvall P, Ericsson CG, Hamsten A. Accumulation of apolipoprotein C-I-rich and cholesterol-rich VLDL remnants during exaggerated postprandial triglyceridemia in normolipidemic patients with coronary artery disease. Circulation 2000;101:227–230.
9. Leung GK, Veniant MM, Kim SK, Zlot CH, Raabe M, Björkegren J, et al. A deficiency of microsomal triglyceride transfer protein reduces apolipoprotein B secretion. J. Biol. Chem. 2000;275:7515–7520.
10. Björkegren J, Veniant M, Kim SK, Withycombe SK, Wood PA, Hellerstein MK, Neese RA, Young SG. Lipoprotein secretion and triglyceride stores in the heart. J. Biol. Chem. 2001;276:38511–38517.
11. Björkegren J, Silveira A, Boquist S, Tang R, Karpe F, Bond MG, de Faire U, Hamsten A. Postprandial enrichment of remnant lipoproteins with apoC-I in healthy normolipidemic men with early asymptomatic atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2002;22:1470–1474.
12. Björkegren J, Beigneux A, Bergo MO, Maher JJ, Young SG. Blocking the secretion of hepatic very low density lipoproteins renders the liver more susceptible to toxin-induced injury. J. Biol. Chem. 2002;277:5476–5483.
13. PROCARDIS Consortium (J Björkegren is a member). A trio family study showing association of the lymphotoxin-alpha N26 (804A) allele with coronary artery disease. Eur. J. Hum. Genet. 2004;12:770–774.
14. Larsson SL, Skogsberg J, Björkegren J. The low density lipoprotein receptor prevents secretion of dense apoB100-containing lipoproteins from the liver. J. Biol. Chem. 2004;279:831-6.
15. Nilsson R, Björkegren J, Tegnér: A powerful differential expression test for probe-level oligonucleotide microarray data. In Proceedings of the 2nd IEEE International Workshop on Genomic Signal Processing and Statistics. 2004; pp. 10–14.
16. Hamsten A, Silveira A, Boquist S, Tang R, Bond MG, de Faire U, Björkegren J. The apolipoprotein CI content of triglyceride-rich lipoproteins independently predicts early atherosclerosis in healthy middle-aged men. J. Am. Coll. Cardiol. 2005;45:1013–1017.
17. Kovacs A, Henriksson P, Hamsten A, Wallen H, Björkegren J, Tornvall P. Hormonal regulation of circulating C-reactive protein in men. Clin. Chem. 2005;51:911–913.
18. Pena JM, Björkegren J, Tegnér J. Growing Bayesian network models of gene networks from seed genes. Bioinformatics 2005;21 (Suppl 2):ii224–ii229.
19. Pena JM, Björkegren J, Tegnér J. Learning dynamic Bayesian network models via cross-validation. Pattern Recognit. Lett. 2005;26:2295–2308.
20. Pena J, Nilsson R, Björkegren J, Tegnér J. Scalable, efficient and correct learning of markov boundaries under the faithfulness assumption. In Proceedings of the Eighth European Conference on Symbolic and Quantitative Approaches to Reasoning under Uncertainty 2005; ECSQARU. Lecture Notes in Artificial Intelligence 3571:136–147.
21. Farrall M, Green FR, Peden J.F, Olsson PG, Clarke R, Hellenius ML, Rust S, Lagercrantz J, Franzosi MG, Schulte H, Carey A, Olsson G, Assmann G, Tognoni G, Collins R, Hamsten A. Watkins H and the PROCARDIS Consortium (J Björkegren is a member). Genome-wide mapping of susceptibility to coronary artery disease identifies a novel replicated locus on chromosome 17. PLoS Genet. 2006;2:e72.
22. Hallen K, Björkegren J, Tegnér J. Detection of compound mode of action by computational integration of whole-genome measurements and genetic perturbations. BMC Bioinformatics 2006;7:51.
23. Nilsson R, Bajic VB, Suzuki H, di Bernardo D, Björkegren J, Katayama S, Reid JF, Sweet MJ, Gariboldi M, Carninci P, Hayashizaki Y, Hume DA, Tegnér J, Ravasi T. Transcriptional network dynamics in macrophage activation. Genomics 2006;88:133–142.
24. Nilsson R, Pena J, Björkegren J, Tegnér J. Evaluating feature selection for SVMs in high dimensions: Springer; 2006. In Proceedings of the 17th European Conference on Machine Learning. Berlin, Germany, September 18–22, 2006. pp 719-726
25. Nilsson R, Björkegren J, Tegnér J. A flexible interpretation for support vector machines. Mathematica J. 2006;10:114–127.
26. Pena J, Nilsson R, Björkegren J, Tegnér J. Identifying the relevant nodes without learning the model. In Proceedings of the Twenty-Second Conference on Uncertainty in Artificial Intelligence 2006;UAI:367–374.
27. Pena J, Nilsson R, Björkegren J, Tegnér J. Reading dependencies from the minimal undirected independence map of a graphoid that satisfies weak transitivity. In Proceedings of the Third European Workshop on Probabilistic Graphical Models 2006;PGM:247–254.
29. Pena J, Nilsson R, Björkegren J, Tegnér J. Evaluating feature selection for SVMs in high dimensions. In Proceedings of Seventeenth European Conference on Machine Learning 2006;ECML:71–726.
30. Pena J, Björkegren J, Tegnér J. Learning and Validating Bayesian Network Models of Gene Networks: Springer; 2006. Advances in Bayesian Networks II.
31. Pena J, Nilsson R, Björkegren J, Tegnér J. Towards scalable and data efficient learning of Markov boundaries. J. Approximate Reasoning 2007;45:211–232.
32. Nilsson R, Pena J, Björkegren J, Tegnér J. Consistent feature selection in polynomial time. J. Machine Learn. Res. 2007;8:589–612.
33. Nilsson R, Pena J, Björkegren J, Tegnér J. Detecting multivariate differential expression patterns. BMC Bioinformatics 2007;8:150.
34. Wågsäter D, Björk H, Zhu C, Björkegren J, Valen G, Hamsten A, Eriksson P. ADAMTS-4 and -8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaques. Atherosclerosis 2008;196:514–522.
35. Kovacs A, Tornvall P, Nilsson R, Tegnér J, Hamsten A, Björkegren J. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci USA 2007;104:13768–13773.
36. Boquist S, Ruotolo G, Skoglund-Andersson C, Tang R, Björkegren J, Bond MG, de Faire U, Brismar K, Hamsten A. Correlation of serum IGF-I and IGFBP-1 and -3 to cardiovascular risk indicators and early carotid atherosclerosis in healthy middle-aged men. Clin. Endocrinol. (Oxf) 2008;68:51–58.
37. Notø AT, Mathiesen EB, Brox J, Björkegren J, Hansen JB. Delayed metabolism of postprandial triglyceride-rich lipoproteins in subjects with echolucent carotid plaques. Lipids 2008;43:353–360.
38. Skogsberg J, Lundström J, Kovacs A, Nilsson R, Noori P, Maleki S, Köhler M, Hamsten A, Tegnér J, Björkegren J. Transcriptional profiling uncovers a network of cholesterol-responsive atherosclerosis target genes. PLoS Genet. 2008;4:e1000036.
39. Notø AT, Mathiesen EB, Brox J, Björkegren J, Hansen JB. The apoC-I content of VLDL particles is associated with plaque size in persons with carotid atherosclerosis. Lipids 2008;43:673–679.
40. Lundström J, Björkegren J, Tegnér J. Evidence of highly regulated genes (in-hubs) in gene networks of Saccharomyces cerevisiae. Bioinform. Biol. Insights 2008;2:313–322.
41. Skogsberg J, Dicker A, Rydén M, Aström G, Nilsson R, Bhuiyan H, Vitols S, Mairal A, Langin D, Alberts P, Walum E, Tegnér J, Hamsten A, Arner P, Björkegren J. ApoB100-LDL acts as a metabolic signal from liver to peripheral fat causing inhibition of lipolysis in adipocytes. PLoS ONE 2008;3:e3771.
42. Gustafsson M, Hörnqvist M, Lundström J, Björkegren J, Tegnér J. Reverse engineering of gene networks with LASSO and non-linear basis functions. Ann. NY Acad. Sci. 2009;1158:265–275.
43. Nilsson R, Björkegren J, Tegnér J. On reliable discovery of molecular signatures. BMC Bioinformatics 2009;101:38.
44. Eriksson, O., Brinne, B., Zhou, Y., Björkegren, J., J. Tegnér. Deconstructing the core dynamics from a complex time-lagged regulatory biological circuit. IET Syst. Biol. 2009;3:113–129.
45. FANTOM Consortium, Suzuki H, Forrest AR, van Nimwegen E, Daub CO, Balwierz PJ, Irvine KM, Lassmann T, Ravasi T, Hasegawa Y, de Hoon MJ, Katayama S, Schroder K, Carninci P, Tomaru Y, Kanamori-Katayama M, Kubosaki A, Akalin A, Ando Y, Arner E, Asada M, Asahara H, Bailey T, Bajic VB, Bauer D, Beckhouse AG, Bertin N, Björkegren J, Brombacher F, Bulger E, Chalk AM, Chiba J, Cloonan N, Dawe A, Dostie J, Engström PG, Essack M, Faulkner GJ, Fink JL, Fredman D, Fujimori K, Furuno M, Gojobori T, Gough J, Grimmond SM, Gustafsson M, Hashimoto M, Hashimoto T, Hatakeyama M, Heinzel S, Hide W, Hofmann O, Hörnquist M, Huminiecki L, Ikeo K, Imamoto N, Inoue S, Inoue Y, Ishihara R, Iwayanagi T, Jacobsen A, Kaur M, Kawaji H, Kerr MC, Kimura R, Kimura S, Kimura Y, Kitano H, Koga H, Kojima T, Kondo S, Konno T, Krogh A, Kruger A, Kumar A, Lenhard B, Lennartsson A, Lindow M, Lizio M, Macpherson C, Maeda N, Maher CA, Maqungo M, Mar J, Matigian NA, Matsuda H, Mattick JS, Meier S, Miyamoto S, Miyamoto-Sato E, Nakabayashi K, Nakachi Y, Nakano M, Nygaard S, Okayama T, Okazaki Y, Okuda-Yabukami H, Orlando V, Otomo J, Pachkov M, Petrovsky N, Plessy C, Quackenbush J, Radovanovic A, Rehli M, Saito R, Sandelin A, Schmeier S, Schönbach C, Schwartz AS, Semple CA, Sera M, Severin J, Shirahige K, Simons C, St Laurent G, Suzuki M, Suzuki T, Sweet MJ, Taft RJ, Takeda S, Takenaka Y, Tan K, Taylor MS, Teasdale RD, Tegnér J, Teichmann S, Valen E, Wahlestedt C, Waki K, Waterhouse A, Wells CA, Winther O, Wu L, Yamaguchi K, Yanagawa H, Yasuda J, Zavolan M, Hume DA; Riken Omics Science Center, Arakawa T, Fukuda S, Imamura K, Kai C, Kaiho A, Kawashima T, Kawazu C, Kitazume Y, Kojima M, Miura H, Murakami K, Murata M, Ninomiya N, Nishiyori H, Noma S, Ogawa C, Sano T, Simon C, Tagami M, Takahashi Y, Kawai J, Hayashizaki Y. The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat. Genet. 2009;41:553–562.
46. Gustafsson, M., Hörnkvist, M., Björkegren, J., and J. Tegnér, J. Genome-Wide System Identification and Analysis Reveals Stable yet Flexible Network Dynamics in Yeast. IET Systems Biology. Genome-wide system analysis reveals stable yet flexible network dynamics in yeast. IET Syst Biol. 2009 Jul;3(4):219.
47. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M; PROCARDIS Consortium (Björkegren). Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009 Dec 24;361(26):2518-28.
48. Hägg S, Skogsberg J, Lundström J, Noori P, Nilsson R, Zhong H, Maleki S, Shang MM, Brinne B, Bradshaw M, Bajic VB, Samnegård A, Silveira A, Kaplan LM, Gigante B, Leander K, de Faire U, Rosfors S, Lockowandt U, Liska J, Konrad P, Takolander R, Franco-Cereceda A, Schadt EE, Ivert T, Hamsten A, Tegnér J, Björkegren J. Multi-organ expression profiling uncovers a gene module in coronary artery disease involving transendothelial migration of leukocytes and LIM domain binding 2: the Stockholm Atherosclerosis Gene Expression (STAGE) study. PLoS Genet. 2009 Dec;5(12):e1000754. Epub 2009 Dec 4.
49. Krapivner S, Iglesias MJ, Silveira A, Tegnér J, Björkegren J, Hamsten A, Van't Hooft FM. DGAT1 Participates in the Effect of HNF4A on Hepatic Secretion of Triglyceride-Rich Lipoproteins. Arterioscler Thromb Vasc Biol. 2010 Feb 18. 47.

REVIEWS
50. Hamsten A, Björkegren J, Boquist S, Nilsson L, Ruotolo G, Eriksson P, Karpe F. Postprandial lipaemia and coronary heart disease. Atherosclerosis 1998. Proceedings of the XIth International Symposium on Atherosclerosis:141–150.
51. Björkegren J. Dual roles of apolipoprotein CI in the formation of atherogenic remnants. Curr. Atheroscler. Rep. 2006;8:1–2.
52. Tegnér J, Björkegren J. Perturbations to uncover gene networks. Trends Genet. 2007;23:34–41.
53. Tegnér J, Nilsson R, Bajic VB, Björkegren J, Ravasi T. Systems biology of innate immunity. Cell. Immunol. 2007;244:105.
54. Tegnér J, Skogsberg J, Björkegren J. Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Multi-organ whole-genome measurements and reverse engineering to uncover gene networks underlying complex traits. J. Lipid Res. 2007;48:267–277.
55. Björkegren J, Tegnér J. Systems biology makes detailed understanding of complex diseases possible. Arteriosclerosis is an example. Läkartidningen 2007;104:3042–3045.
56. Björkegren J, Tegnér J. Systembiologin formar ny preventiv hälsovård. Läkartidningen 2007;104:3036, 2007.
57. Björkegren J. Atherosclerosis—A network of genes driven by environmental pressures filtered through the genetic make-up of the individual. International Atherosclerosis Society (IAS) Commentary online.
58. Tegnér J, Björkegren J, Ravasi T, Bajic V. Transcription Regulatory Network Analysis Using CAGE. John Wiley & Sons, Chichester, UK, 2008.

Publikatsioonid

Klass
Aasta
Publikatsioon
 
1.1.
2015
1.1.
2015
1.1.
2014
1.1.
2014
1.1.
2013
1.1.
2012
1.1.
2011
1.1.
2011
1.1.
2011
1.1.
2011
1.2.
2011
1.1.
2010
1.1.
2009
1.1.
2009
1.1.
2009
1.1.
2009
1.1.
2009
1.1.
2009
1.1.
2009
1.1.
2008
1.1.
2008
1.1.
2008
1.1.
2008
1.1.
2008
1.1.
2008
1.1.
2007
1.1.
2007
1.1.
2007
1.1.
2007
1.1.
2007
1.1.
2007
1.1.
2007
1.2.
2007
3.1.
2007
1.1.
2006
1.1.
2006
1.1.
2006
1.1.
2006
1.2.
2006
3.4.
2006
3.4.
2006
1.1.
2005
1.1.
2005
1.1.
2005
1.1.
2005
1.1.
2005
1.1.
2004
1.1.
2002
1.1.
2002
1.1.
2001
1.1.
2000
1.1.
2000
1.1.
1999
1.1.
1999
1.1.
1998
1.1.
1998
12.07.2019
  • Found 3 results
ProgramTypeNumberNameProject startProject endPrincipal investigatorInstitutionFinancing
IUTIUT20-46Translational studies on bone and muscle pathologies01.01.201431.12.2019Aare MärtsonUniversity of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine699 600,00 EUR
1.1.5.3.4.1.3.2.2.SP1GI18436TUtilising myocardial infarction genes for better treatment (druggable-MI-genes)01.09.201831.08.2021Andres MetspaluUniversity of Tartu, Institute of Genomics145 368,96 EUR
ETFETF8853Causal Tissue and Cross-Tissue Gene Networks in Coronary Artery Disease01.01.201131.12.2014Lars Johan Markus BjörkegrenUniversity of Tartu, Faculty of Medicine80 112,00 EUR